|
|
|
Brain (101065)
Sponsor: MUSC (101065)
|
By Malignant Hematology on
7/5/2008 10:00 AM
|
|
|
Expanded Access Protocol for Purging Blood Stem Cells or Bone Marrow from Patients with High-Risk Neuroblastoma Prior to Autologous Transplantation Under FDA Investigational Device Exemption BB-IDE-2259
None Available
|
 |
|
|
More...
|
|
|
|
|
|
|
Leukemia (100837)
Sponsor: SWOG (S0106)
|
By Malignant Hematology on
7/5/2008 10:00 AM
|
|
|
A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg) Induction Therapy Versus Standard Induction with Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy with Gemtuzumab Ozogamicin (Mylotarg) or No Additional Therapy for Patients Under Age 56 with Previously Untreated DeNovo Acute Myeloid Leukemia (AML)
HIPAA Authorization
Informed Consent - Intervention
Protocol
|
|
|
|
|
More...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|